Prelude Capital Management, LLC Crispr Therapeutics Ag Transaction History

Prelude Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	BUY	$110.2 - $156.64 $220 - $313	2 Added 0.09%	2,117 $237,000
Q2 2021 Aug 16, 2021	BUY	$100.84 - $161.89 $213,276 - $342,397	2,115 New	2,115 $342,000
Q4 2020 Feb 16, 2021	SELL	$79.67 - $173.23 $122,452 - $266,254	-1,537 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$78.5 - $100.64 $267,920 - $343,484	-3,413 Reduced 68.95%	1,537 $129,000
Q2 2020 Aug 14, 2020	BUY	$38.5 - $76.05 $190,575 - $376,447	4,950 New	4,950 $364,000
Q3 2019 Nov 14, 2019	SELL	$40.99 - $52.56 $305,211 - $391,361	-7,446 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$35.45 - $48.2 $263,960 - $358,897	7,446 New	7,446 $351,000
Q3 2018 Nov 14, 2018	SELL	$44.35 - $65.71 $225,209 - $333,675	-5,078 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$42.62 - $73.59 $257,978 - $445,440	-6,053 Reduced 54.38%	5,078 $298,000
Q1 2018 May 15, 2018	SELL	$23.52 - $58.17 $328,692 - $812,925	-13,975 Reduced 55.66%	11,131 $509,000
Q4 2017 Feb 14, 2018	BUY	$16.95 - $23.48 $425,546 - $589,488	25,106	25,106 $589,000

493

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.97B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.